There are 594 resources available
Q&A and discussion
Session: Biology and novel agents in SCLC
Resources:
Webcast
Q&A and discussion
Session: Biomarker testing: Sharing experiences among the countries
Resources:
Webcast
Introduction and first vote
Presenter: Myung-Ju Ahn
Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?
Resources:
Slides
Webcast
Osimertinib monotherapy remains our current standard of care
Presenter: Zofia Piotrowska
Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?
Resources:
Slides
Webcast
The time for TKI combinations is now
Presenter: Antonio Passaro
Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?
Resources:
Slides
Webcast
Second vote and conclusions/discussion
Presenter: Myung-Ju Ahn
Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?
Resources:
Slides
Webcast
AI in lung cancer pathology
Presenter: Jakob Kather
Session: The role of AI in lung cancer
Resources:
Slides
Webcast
Refining the definition of oligometastatic disease: Integrating biological insights
Presenter: Ashley Horne
Session: Advances in oligometastatic disease
Resources:
Slides
Webcast
AI in lung cancer imaging
Presenter: Florian Fintelmann
Session: The role of AI in lung cancer
Resources:
Slides
Webcast
AI in response assessment
Presenter: Arsela Prelaj
Session: The role of AI in lung cancer
Resources:
Slides
Webcast